Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Opdivo Extends Label for Frontline Bladder Cancer in South Korea
July 19, 2024
- Renalys Raises 6 Billion Yen in Series A Financing to Push IgA Med
July 18, 2024
- BMS Files Hypertrophic Cardiomyopathy Drug in Japan
July 18, 2024
- Eisai Hands Over Fosravuconazole Rights in Asia/Oceania to Sato
July 17, 2024
- Kissei Clears Primary Goal for Linzagolix in Japan PIII
July 17, 2024
- Sumitomo Nabs FDA’s Fast-Track Tag for Cancer Med DSP-5336
July 17, 2024
- Insmed Set to Double Japan Staff by 2025-End as It Gears Up for Brensocatib Debut
July 17, 2024
- Senju/Mochida's Dry Eye Med Scores PIII Primary Endpoint
July 17, 2024
- LTL, Cheplapharm Envision Heightened Opportunities for LLP Takeovers under Elective Care Scheme
July 16, 2024
- Meiji Paints Consortium Plan of Its Own, Woos Generic Peers to Join Scheme
July 16, 2024
- Shonan iPark Commences Full-Fledged Operations in South Korea
July 16, 2024
- Ex-Teva Takeda Chief Matsumori to Lead Daito
July 16, 2024
- AbbVie Files Venclexta for Mantle Cell Lymphoma in Japan
July 16, 2024
- FDA Snubs MEDRx/DWTI’s Lidocaine Patch Yet Again
July 16, 2024
- Japan CGP Market Projected at 54 Billion Yen by 2035: Fuji Keizai
July 16, 2024
- Meiji Looks at Sales of 274 Billion Yen from Pharma Biz in FY2026
July 12, 2024
- Leqembi Approved in Hong Kong, Israel: Eisai
July 12, 2024
- Chiesi Joins Japan Rare Disease Market, Shoots for 10 Billion Yen Sales by 2030
July 12, 2024
- FY2023 Logs Gyration in COVID Drug Sales, Stark Contrast for Ronapreve, Lagevrio
July 11, 2024
- Taiho Bags Japan, Asian Rights to Arcus’ CD73 Inhibitor
July 10, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…